Alaunos CEO granted 3,700 shares as salary

Weis Holger reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 05/27/2026 - 04:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Weis Holger reported acquisition or exercise transactions in this Form 4 filing.

Alaunos Therapeutics, Inc. reported that Chief Executive Officer Holger Weis received a stock-based compensation grant. On May 22, 2026, he was issued 3,700 shares of common stock at $2.37 per share in lieu of net salary. Following this award, Weis directly holds 4,911 shares of Alaunos common stock. This transaction is classified as a grant or award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 3,700 shares

Grant/Award 1 txn

Insider Weis Holger

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,700	$2.37	$9K

Holdings After Transaction: Common Stock — 4,911 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock issued in lieu of net salary.

Key Figures

Shares granted: 3,700 shares Grant price: $2.37 per share Shares held after grant: 4,911 shares

3 metrics

Shares granted 3,700 shares Common stock grant on May 22, 2026

Grant price $2.37 per share Value used for stock issued in lieu of salary

Shares held after grant 4,911 shares CEO Holger Weis direct holdings post-transaction

Key Terms

Grant, award, or other acquisition, Common Stock, issued in lieu of net salary

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

issued in lieu of net salary financial

"Represents shares of common stock issued in lieu of net salary."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alaunos Therapeutics (TCRT) report for its CEO?

Alaunos reported that CEO Holger Weis received a grant of 3,700 shares of common stock. The award was issued on May 22, 2026 at $2.37 per share as stock-based compensation in lieu of net salary.

Was the Alaunos Therapeutics (TCRT) CEO transaction a market purchase or sale?

No, the CEO’s transaction was not an open-market trade. It was classified as a grant or award acquisition, with 3,700 Alaunos common shares issued to him as compensation instead of net salary on May 22, 2026.

How many Alaunos Therapeutics (TCRT) shares does the CEO hold after this Form 4?

After the grant, CEO Holger Weis directly holds 4,911 shares of Alaunos common stock. This total reflects his position following the 3,700-share award issued in lieu of net salary at $2.37 per share.

At what price were the Alaunos Therapeutics (TCRT) CEO’s compensation shares recorded?

The 3,700 Alaunos common shares granted to CEO Holger Weis were recorded at $2.37 per share. This price represents the value used for the stock-based compensation issued instead of his cash net salary on May 22, 2026.

What does “issued in lieu of net salary” mean for Alaunos Therapeutics (TCRT)?

“Issued in lieu of net salary” means the CEO received company shares instead of taking that portion of pay in cash. For this transaction, Alaunos granted 3,700 common shares to Holger Weis as compensation rather than paying equivalent net salary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weis Holger

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD. SUITE 300

(Street)

FORT LAUDERDALE FLORIDA 33301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		A		3,700(1)	A	$2.37	4,911	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of net salary.

	/s/ Weis, Holger	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)